TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27488272

Group type: EXPERIMENTAL
Intervention: Three-phase multifaceted intervention including academic detailing with a pharmacist, GP-led medicines reviews, web-based pharmaceutical treatment algorithms, and tailored patient information leaflets
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: GP-led medicines reviews with patients present
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Standardised academic detailing session
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Patient information leaflets
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Overall experience of the intervention
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Organisational barriers
Number of subjects: 196
Study: 24392890

Group type: EXPERIMENTAL
Intervention: pECMO
Number of subjects: 37

Group type: COMPARATOR
Intervention: cECMO
Number of subjects: 37
Study: 18302601

Group type: EXPERIMENTAL
Intervention: Roy Adaptation Model‐based experimental education, exercise and social support programme
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 15215009

Group type: EXPERIMENTAL
Intervention: Flow-trigger (FT) sensing on Servo 300 ventilator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pressure-trigger (PT) sensing on Servo 300 ventilator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pressure-trigger (PT) sensing on Servo 900C ventilator
Number of subjects: 16
Study: 10689295

Group type: EXPERIMENTAL
Intervention: 20 mg nefopam as Acupan(R) administered as a 5‐ or 20‐min intravenous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control) administered to subjects during the control phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro binding assays and antinociceptive tests in rats and mice
Number of subjects: 0
Study: 9366277

Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet plus placebo
Number of subjects: 0
Study: 8347851

Group type: EXPERIMENTAL
Intervention: GM-CSF (10 micrograms/kg intravenously over 6 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2424471

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and nutritional supplementation
Number of subjects: 0
Study: 30121630

Group type: EXPERIMENTAL
Intervention: Spironolactone treatment for 9 months
Number of subjects: 146

Group type: COMPARATOR
Intervention: Matched controls (not treated with spironolactone)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Spironolactone treatment for 9 months (within-person analysis)
Number of subjects: 146
Study: 28662715

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for paranoia (CBM-pa)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Text-reading control intervention
Number of subjects: 60
Study: 25637909

Group type: EXPERIMENTAL
Intervention: 10-session individual and group cognitive behavior therapy (CBT) for anxiety disorders
Number of subjects: 182
Study: 24408900

Group type: EXPERIMENTAL
Intervention: Detailed consent document with graphics
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Detailed consent document without graphics
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard consent document with graphics
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard consent document without graphics
Number of subjects: 85
Study: 21950587

Group type: EXPERIMENTAL
Intervention: Night guard (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mouthwash (Group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Night guard and mouthwash (Group C)
Number of subjects: 105
Study: 19430060

Group type: EXPERIMENTAL
Intervention: Oral Iron polymaltose complex (IPC), n=59
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oral Ferrous sulfate (FS), n=59
Number of subjects: 118
Study: 17088340

Group type: EXPERIMENTAL
Intervention: variable‐flow Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: conventional NCPAP
Number of subjects: 13

Group type: COMPARATOR
Intervention: nasal cannulae
Number of subjects: 13
Study: 15060518

Group type: EXPERIMENTAL
Intervention: L-DOPA (200 mg) and benserazide (50 mg) administered 1 hour before sleeping for 30 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physical exercise program on a manual bicycle ergometer for 45 days (3 times a week)
Number of subjects: 13
Study: 11309057

Group type: EXPERIMENTAL
Intervention: Watchful waiting for 12 weeks
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 639

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 639
Study: 9215056

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.4% oxybuprocaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sub‐Tenon's infiltration with 2% lignocaine
Number of subjects: 35
Study: 8356979

Group type: EXPERIMENTAL
Intervention: 4,200 kJ/d diet with combined aerobic and anaerobic exercise
Number of subjects: 121

Group type: COMPARATOR
Intervention: 4,200 kJ/d diet
Number of subjects: 121
Study: 3630992

Group type: EXPERIMENTAL
Intervention: Soy-lactose formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soy formula with sucrose or maltose
Number of subjects: 40
Study: 28682122

Group type: EXPERIMENTAL
Intervention: Maternal verbal imitations
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fluency and connection in mother-infant dyads
Number of subjects: 249
Study: 27406638

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) prophylaxis administered from 6 weeks of age
Number of subjects: 1298

Group type: COMPARATOR
Intervention: No cotrimoxazole (CTX) prophylaxis
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) prophylaxis
Number of subjects: 1298
Study: 24076367

Group type: EXPERIMENTAL
Intervention: Bronchodilator tiotropium (18 mcg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bronchodilator salmeterol (50 mcg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg once daily for 2 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral placebo (for 2 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-treatment (4 weeks after cessation of prednisolone)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dyspnea VAS score after 2 weeks of treatment
Number of subjects: 28
Study: 23592936

Group type: EXPERIMENTAL
Intervention: FDTV 2 mg/180 mg once per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: T 2 mg once per day
Number of subjects: 40
Study: 20722328

Group type: EXPERIMENTAL
Intervention: PACT programme
Number of subjects: 686

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 686
Study: 18417461

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg once daily plus a calorie-restricted diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg once daily plus a calorie-restricted diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg and 5 mg
Number of subjects: 0
Study: 15917157

Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐oestradiol, 300 microg daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Transdermal matrix patch 17beta‐oestradiol, 50 microg/day
Number of subjects: 132
Study: 14651310

Group type: EXPERIMENTAL
Intervention: Family-centered intervention for sleep disturbed infants
Number of subjects: 33
Study: 11029964

Group type: EXPERIMENTAL
Intervention: Basal feed + rapeseed oil (60 g/kg feed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Basal feed + rapeseed oil (60 g/kg feed) + vitamin E (200 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Basal feed (no added fat or vitamin E)
Number of subjects: 12
Study: 8996852

Group type: EXPERIMENTAL
Intervention: Ofloxacin (n = 28)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ceftriaxone (n = 24)
Number of subjects: 52
Study: 1464126

Group type: EXPERIMENTAL
Intervention: Nifedipine (bolus 3 micrograms.kg‐1.min‐1 for 5 min and maintenance 0.2 micrograms.kg‐1.min‐1 for 4 hours)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study: 6398126

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Myconazole
Number of subjects: 90
Study: 29545462

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 26943128

Group type: EXPERIMENTAL
Intervention: Early introduction of six allergenic foods (peanut, cooked egg, cow's milk, sesame, whitefish, and wheat)
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Standard practice of exclusive breast‐feeding to approximately 6 months of age
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Early introduction of six allergenic foods
Number of subjects: 1303
Study: 24859430

Group type: EXPERIMENTAL
Intervention: Regular supervised aquatic exercise (low-intensity aerobic aquatic exercise, twice a week for 10 years)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of study groups
Number of subjects: 16
Study: 22730113

Group type: EXPERIMENTAL
Intervention: Dexamethasone with thalidomide (200 mg daily) for 12 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 108
Study: 20617214

Group type: EXPERIMENTAL
Intervention: 5 cmH2O PEEP
Number of subjects: 75

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 75
Study: 17398026

Group type: EXPERIMENTAL
Intervention: <70 Gy
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: 70-74.9 Gy
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: 75-79.9 Gy
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: >=80 Gy
Number of subjects: 1530
Study: 15767226

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention
Number of subjects: 162
Study: 12031363

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with oral nifedipine and deflazacort
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no adjunctive treatment)
Number of subjects: 80
Study: 9822140

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined thiazide and potassium-sparing diuretic
Number of subjects: 0
Study: 7521907

Group type: EXPERIMENTAL
Intervention: Filgrastim 10 micrograms/kg/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Filgrastim 20 micrograms/kg/d
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no filgrastim)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Filgrastim (both doses combined)
Number of subjects: 43
Study: 2697435

Group type: EXPERIMENTAL
Intervention: Human recombinant GM-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled trial (not specified)
Number of subjects: 0
Study: 972274

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (Tobramycin and Gentamicin)
Number of subjects: 75
Study: 31487750

Group type: EXPERIMENTAL
Intervention: Structured inpatient intervention including an education programme
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Structured inpatient intervention
Number of subjects: 81
Study: 31714640

Group type: EXPERIMENTAL
Intervention: Systematic TDM of newer generation AEDs
Number of subjects: 151

Group type: COMPARATOR
Intervention: Rescue TDM of newer generation AEDs
Number of subjects: 151
Study: 31196813

Group type: EXPERIMENTAL
Intervention: Solithromycin 1000 mg (single dose oral)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg (intramuscular) plus Azithromycin 1000 mg (oral)
Number of subjects: 262
Study: 28049079

Group type: EXPERIMENTAL
Intervention: Extended early intervention (Extended EI, 3-year EI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Step-down psychiatric care (SC, 2-year EI)
Number of subjects: 160
Study: 25670542

Group type: EXPERIMENTAL
Intervention: RT + EPO
Number of subjects: 141

Group type: COMPARATOR
Intervention: RT
Number of subjects: 141
Study: 23972555

Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) offered by lay counsellors
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT)
Number of subjects: 1694
Study: 21130937

Group type: EXPERIMENTAL
Intervention: Treatment interventions for complicated grief
Number of subjects: 14

Group type: COMPARATOR
Intervention: Preventive interventions for complicated grief
Number of subjects: 14
Study: 19117900

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 89

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 89
Study: 17474857

Group type: EXPERIMENTAL
Intervention: Soy intake (highest quartile)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Low soy intake (lowest quartile)
Number of subjects: 380

Group type: COMPARATOR
Intervention: High fiber, fruit, or vegetable intake
Number of subjects: 380
Study: 14735173

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Timing of DA
Number of subjects: 368
Study: 11149497

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Cefamandole/gentamicin
Number of subjects: 163
Study: 9184363

Group type: EXPERIMENTAL
Intervention: iv meropenem 1 g tds
Number of subjects: 161

Group type: COMPARATOR
Intervention: iv cefotaxime 1 g tds and iv metronidazole 500 mg tds
Number of subjects: 161
Study: 1351538

Group type: EXPERIMENTAL
Intervention: Prolonged chemotherapy (with tamoxifen for postmenopausal patients)
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Single perioperative cycle
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PeCT)
Number of subjects: 1506

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1506
Study: 3157296

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 44
Study: 3114351

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin (16 h/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous transdermal nitroglycerin (24 h/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31050809

Group type: EXPERIMENTAL
Intervention: Scalar Age of Blood Index (SBI)
Number of subjects: 0
Study: 28436092

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (supplement (+) group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: No creatine supplementation (supplement (-) group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 25092530

Group type: EXPERIMENTAL
Intervention: CBT anger management group intervention
Number of subjects: 11
Study: 23178541

Group type: EXPERIMENTAL
Intervention: Grade III posteroanterior mobilization (3 cycles of 60s)
Number of subjects: 39
Study: 21983766

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: valsartan 160 mg
Number of subjects: 60
Study: 18434906

Group type: EXPERIMENTAL
Intervention: Early feeding within 24 hours of admission
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed feeding on day 4 of admission
Number of subjects: 28
Study: 16931217

Group type: EXPERIMENTAL
Intervention: Once-daily sevelamer dosing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thrice-daily sevelamer dosing
Number of subjects: 24
Study: 14519149

Group type: EXPERIMENTAL
Intervention: Budesonide-treated asthmatics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-treated asthmatics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined asthma groups (both budesonide and placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-asthmatics
Number of subjects: 0
Study: 11110230

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/100 mg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/16 mg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/50 mg plus HCTZ 12.5 mg
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg plus HCTZ 12.5 mg
Number of subjects: 1161
Study: 8882193

Group type: EXPERIMENTAL
Intervention: Oral artemether (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral artesunate (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Number of subjects: 120
Study: 1407887

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (75 micrograms)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sequential combined hormone replacement therapy (various regimens)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (10 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (1 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 4061431

Group type: EXPERIMENTAL
Intervention: Outpatient treatment with follow-up interviews
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Temporal analyses of drinking behavior data
Number of subjects: 48
Study: 30661249

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q8W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 29781302

Group type: EXPERIMENTAL
Intervention: Additional Family-Based Treatment (FBT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Alternate Treatment Group
Number of subjects: 69
Study: 27737427

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation with positive end-expiratory pressure valve
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation without positive end-expiratory pressure valve
Number of subjects: 28

Group type: COMPARATOR
Intervention: Manual hyperinflation (both with and without valve)
Number of subjects: 28
Study: 25010302

Group type: EXPERIMENTAL
Intervention: Arm-crank exercise program (12 weeks, 3 sessions/week, moderate intensity 50-65% HRR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Arm-crank exercise program (12 weeks, 3 sessions/week)
Number of subjects: 17
Study: 22352947

Group type: EXPERIMENTAL
Intervention: Media-exposed intervention group (watched programming with media intervention)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (watched programming without media intervention)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Media-exposed intervention group
Number of subjects: 228
Study: 20522617

Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment after 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment after 2 to 3 weeks
Number of subjects: 0
Study: 18161896

Group type: EXPERIMENTAL
Intervention: Honey-impregnated dressings
Number of subjects: 368

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 368
Study: 12378193

Group type: EXPERIMENTAL
Intervention: Lactase-treated feeds
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (standard feeds)
Number of subjects: 130
Study: 9857457

Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 130 bpm in group II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 110 bpm in group I
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Upper tracking rate of 130 bpm in group I
Number of subjects: 20
Study: 9385104

Group type: EXPERIMENTAL
Intervention: Proposed tests for treatment effect on time to disease under informative censoring assumptions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weighted log-rank tests.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semiparametric estimators for treatment effect.
Number of subjects: 0
Study: 2136872

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 224125

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate preparation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Otosporin
Number of subjects: 49
Study: 31970563

Group type: EXPERIMENTAL
Intervention: CO2 laser (0.066 J/cm2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated fluoride gel and CO2 laser (0.066 J/cm2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 5% fluoride varnish
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sealant (control)
Number of subjects: 61
Study: 30008038

Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Walking (HIIW) - 3 × 5 min bursts at 80% VO2 max, separated by 5 min of walking at 30% VO2 max
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous Moderate Intensity Walking (CMW) - 60% VO2 max for 30 min
Number of subjects: 17
Study: 27317101

Group type: EXPERIMENTAL
Intervention: Advantix® (50% permethrin/10% imidacloprid)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NexGard™
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 32

Group type: COMPARATOR
Intervention: Negative placebo control
Number of subjects: 32
Study: 24614832

Group type: EXPERIMENTAL
Intervention: Microwave diathermy (MD) treatment and exercises
Number of subjects: 39

Group type: COMPARATOR
Intervention: Exercises only (Control)
Number of subjects: 39
Study: 22458574

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (UFH + GPI)
Number of subjects: 3602